Epoprostenol

اپوپروستنول

⚠ Unverified

🩸 Blood And Blood Forming OrgansProstacyclin

Market / country: 🇺🇸 USA

Flolan (US) · Veletri (US)

🧮 Dose calculator

Pulmonary arterial hypertension (PAH) · Regimen source: FDA Epoprostenol · 2.1FDA Epoprostenol · 2.2

⛔ Increase by 2 ng/kg/min every ≥15 min to tolerance; chronic adjustments in 1–2 ng/kg/min steps. Reconstitute only with sterile water or saline; do not mix with other drugs. Avoid abrupt withdrawal or large reductions (rebound, death). FDA Epoprostenol · 2.1FDA Epoprostenol · 2.2

🛡️ Safety & information

Contraindications

  • ⛔ Chronic use in heart failure due to severe left ventricular systolic dysfunction; pulmonary oedema during dose initiation; hypersensitivity. FDA Epoprostenol · 4

Warnings

  • • Hypotension and flushing at initiation; rebound symptoms on withdrawal; catheter infection; bleeding (platelet inhibition). FDA Epoprostenol · 5

Formulations

👥 Special populations

  • 🤰 PregnancyUse with caution

    Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Epoprostenol · 8.1

    “Risk Summary Limited published data from case series and case reports with Epoprostenol for Injection have not established a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes when used during pregnancy.”
  • 🤱 BreastfeedingUse with caution

    Label: use with caution while breastfeeding; see the label text. FDA Epoprostenol · 8.2

    “Risk Summary There are no data on the presence of epoprostenol in either human or animal milk, the effects on the breastfed infant, or the effect on milk production.”
  • 👶 ChildrenSafety not established

    Label: safety and effectiveness in children have not been established. FDA Epoprostenol · 8.4

    “Safety and effectiveness in pediatric patients have not been established.”
  • 👴 Older adultsUse with caution

    Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Epoprostenol · 8.5

    “In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.”
  • ⚥ Females & males of reproductive potentialNo data

    The source for this drug has no section for this group.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

🔗 Similar drugs

Doz is only a support tool and does not replace clinical judgment or official sources. Check every dose against the original source before prescribing. About & disclaimer · Sources

Information on this site is compiled from online websites and references. Doz accepts no responsibility for self-medication without approval from a physician and a reliable reference, or for any consequences of using this information.

Inspired by the Saphira project; part of the content is taken from it.

For suggestions, corrections, adding drugs or anything else, you can contact me on Telegram: @cenaav